Incorporating systems thinking into drug value assessment promises more realistic evaluations of the impact of new therapies, but it requires buy-in from policy makers, biopharmaceutical firms, ...
Kimberly Westrich, MA, of the National Pharmaceutical Council, explained how she envisions value assessment tools to be used in the US health care system in coming years. How do you envision the ...
The recent reauthorization of the Patient-Centered Outcomes Research Institute (PCORI) comes with an expanded mandate to study the economic impacts of treatments presenting new opportunities for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results